News | May 11, 2024
Neuland Laboratories posts Q4 FY24 consolidated PAT at Rs. 67.56 Cr
Neuland Laboratories has reported total income of Rs. 390.36 crores during the period ended March 31, 2024
Neuland Laboratories has reported total income of Rs. 390.36 crores during the period ended March 31, 2024
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
With this, for all our USFDA facilities, EIRs are in place
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
The USFDA has issued 5 observations pursuant to the completion of audit
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)